HER2-enriched subtype and pathological complete response in HER2-positive breast cancer: a systematic review and meta-analysis
Abstract Background HER2-positive (HER2+) breast cancer (BC) comprises all the four
PAM50 molecular subtypes. Among these, the HER2-Enriched (HER2-E) appear to be …
PAM50 molecular subtypes. Among these, the HER2-Enriched (HER2-E) appear to be …
HER2‐positive breast cancer brain metastasis: a new and exciting landscape
AS Zimmer, AED Van Swearingen… - Cancer …, 2022 - Wiley Online Library
Abstract Background Brain metastases (BrM) incidence is 25% to 50% in women with
advanced human epidermal growth factor receptor 2 (HER2)‐positive breast cancer …
advanced human epidermal growth factor receptor 2 (HER2)‐positive breast cancer …
Beyond an updated graded prognostic assessment (breast GPA): a prognostic index and trends in treatment and survival in breast cancer brain metastases from 1985 …
Purpose Brain metastases are a common sequelae of breast cancer. Survival varies widely
based on diagnosis-specific prognostic factors (PF). We previously published a prognostic …
based on diagnosis-specific prognostic factors (PF). We previously published a prognostic …
[HTML][HTML] Understanding patterns of brain metastasis in breast cancer and designing rational therapeutic strategies
EM Brosnan, CK Anders - Annals of translational medicine, 2018 - ncbi.nlm.nih.gov
One of the most feared sequelae after a diagnosis of advanced breast cancer is
development of metastases to the brain as this diagnosis can affect physical function …
development of metastases to the brain as this diagnosis can affect physical function …
[HTML][HTML] Treatment and outcomes of patients in the Brain Metastases in Breast Cancer Network Registry
I Witzel, E Laakmann, R Weide, T Neunhoeffer… - European Journal of …, 2018 - Elsevier
Abstract Background Brain metastases (BMs) have a major impact on life expectancy and
quality of life for many breast cancer patients. Knowledge about treatment patterns and …
quality of life for many breast cancer patients. Knowledge about treatment patterns and …
The role of tyrosine kinase inhibitors in the treatment of HER2+ metastatic breast cancer
F Le Du, V Dièras, G Curigliano - European Journal of Cancer, 2021 - Elsevier
The introduction of trastuzumab and other subsequent human epidermal growth factor
receptor 2 (HER2)–targeted therapies dramatically shifted the treatment landscape of …
receptor 2 (HER2)–targeted therapies dramatically shifted the treatment landscape of …
Prognostic factors of brain metastasis and survival among HER2-positive metastatic breast cancer patients: a systematic literature review
MD Hackshaw, HE Danysh, M Henderson, E Wang… - BMC cancer, 2021 - Springer
Background Patients with breast cancer who overexpress the human epidermal growth
factor receptor 2 (HER2) and subsequently develop brain metastasis (BM) typically …
factor receptor 2 (HER2) and subsequently develop brain metastasis (BM) typically …
Targeting cell cycle progression in HER2+ breast cancer: an emerging treatment opportunity
N Koirala, N Dey, J Aske, P De - International Journal of Molecular …, 2022 - mdpi.com
Layman summary HER2 is an oncogenic driver in a subset of breast cancer. Despite the fact
that there are the options of several anti-HER2 targeted therapies, most patients with …
that there are the options of several anti-HER2 targeted therapies, most patients with …
Advances in targeting HER2-positive breast cancer
N Harbeck - Current Opinion in Obstetrics and Gynecology, 2018 - journals.lww.com
Advances in targeting HER2-positive breast cancer : Current Opinion in Obstetrics and
Gynecology Advances in targeting HER2-positive breast cancer : Current Opinion in Obstetrics …
Gynecology Advances in targeting HER2-positive breast cancer : Current Opinion in Obstetrics …
LCCC 1025: a phase II study of everolimus, trastuzumab, and vinorelbine to treat progressive HER2-positive breast cancer brain metastases
AED Van Swearingen, MB Siegel, AM Deal… - Breast cancer research …, 2018 - Springer
Purpose HER2+ breast cancer (BC) is an aggressive subtype with high rates of brain
metastases (BCBM). Two-thirds of HER2+ BCBM demonstrate activation of the PI3K/mTOR …
metastases (BCBM). Two-thirds of HER2+ BCBM demonstrate activation of the PI3K/mTOR …